July 18, 2022 Unpacking Royalty Pharma The serial acquirer of royalty interests is coming into its own, but the secret to its success lies in cystic fibrosis.
July 14, 2022 Theravance gets a fresh start Meanwhile, Royalty Pharma bets that Trelegy will do better than the sellside expects.
September 19, 2017 One chance for Glaxo’s triple The UK company's triple combo just got US approval, and now the group must meet rising analyst expectations.
September 08, 2017 Upcoming events – GSK’s triple COPD play and data for Xtandi in earlier stage prostate cancer